EVT801 Is Well Tolerated, Elicits Disease Control in Advanced Ovarian Cancer
Treatment with EVT801 was well tolerated and led to a stable disease rate of 46% in patients with advanced ovarian cancer.
Treatment with EVT801 was well tolerated and led to a stable disease rate of 46% in patients with advanced ovarian cancer.
Data from the phase 3 CRC-PREVENT trial support the sensitivity of ColoSense in the detection of colorectal cancer.
During a Case-Based Roundtable® event, Julia Rotow, MD, led a discussion on the non-clinical barriers that impact the use of using next-generation sequencing for patients…
Fuzuloparib with or without apatinib provided superior PFS benefit vs chemotherapy in HER2– metastatic breast cancer harboring germline BRCA1/2 mutations.
Abstract. BTK inhibitors (BTKis) are established standards of care in multiple B-cell malignancies including chronic lymphocytic leukemia, mantle cell lymp
After receiving a metastatic colorectal cancer diagnosis, Jeff Williams was told he didn’t qualify for surgery. After coming to MD Anderson for a second opinion,…
Assisting Healthcare Providers with Expanded Access Requests for Investigational Oncology Products
An abstract is unavailable.
Mohamad Mohty, MD, PhD, highlights key takeaways from the 50th Annual EMBT Meeting, focusing on ongoing efforts within the GVHD treatment arena.
Felicitas Thol, MD, Hannover Medical School, Hannover, Germany, discusses the value of measurable residual disease (MRD) in guiding treatment decisions post-allogeneic stem cell transplantation (alloSCT)…
The BLA for zenocutuzumab to treat NRG1-positive non–small cell lung cancer and pancreatic cancer received priority review from the FDA.